PERT shortages: How GPs can support patients impacted by supply issues

Getty/ALEKSEI BEZRUKOV

By Julie Penfold

Pancreatic enzyme replacement therapy (PERT) products such as Creon, Nutrizym and Pancrex have been hit by supply issues that experts have warned may continue until 2026.

For patient living with conditions such as pancreatic cancer, chronic pancreatitis and cystic fibrosis who require PERT on an ongoing basis, the situation could have a detrimental effect on their health.